Feeds › FDA approvals and clearances
FDA approvals and clearances
New drugs and biologics the FDA approved, and the devices it cleared or approved, from openFDA, with the public companies among the applicants.
About this data
- What it is
- The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
- Who files it
- The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
- How current
- We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
- Terms
- openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
- Worth knowing
- This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
- Not to be confused with
- Clinical trial updates: what sponsors report about their studies, not what the FDA decided.
All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.
Source and freshness · Information, not investment advice (disclaimer).
FDA decisions per day, last 30 days
Brand-name drugs and biologics, with supplements Device clearances and approvals
By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.
Latest FDA decisions
Showing: ticker GEHC · Everything
| Decided | Product | ApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed. | DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective. | FDA page |
|---|---|---|---|---|
| Sep 1, 2026 | Carescape ONE; Carescape Dock F0; TruSignal ECG MM; TruSign… | GEHC GE Healthcare Finland Oy | Device clearance (510(k)) Traditional | K260656 ↗ |
| Aug 28, 2026 | Carescape Canvas 1000; Carescape Canvas Smart Display | GEHC GE Healthcare Finland Oy | Device clearance (510(k)) Traditional | K260343 ↗ |
| Mar 23, 2026 | True Definition DL | GEHC Ge Healthcare Japan Corporation | Device clearance (510(k)) Traditional | K253686 ↗ |
| Jan 23, 2026 | 3.0T AIR 32CH HNA | GEHC Ge Healthcare Coils (Usa Instruments, Inc.) | Device clearance (510(k)) Abbreviated | K253738 ↗ |
| Jan 8, 2026 | View | GEHC GE Healthcare | Device clearance (510(k)) Traditional | K253639 ↗ |
| Dec 15, 2025 | CLARISCAN GADOTERATE MEGLUMINE | GEHC GE Healthcare | Generic (ANDA), supplement Labeling | ANDA210016 ↗ |
| Dec 15, 2025 | CLARISCAN GADOTERATE MEGLUMINE | GEHC GE Healthcare | Generic (ANDA), supplement Labeling | ANDA210016 ↗ |
| Dec 15, 2025 | CLARISCAN GADOTERATE MEGLUMINE | GEHC GE Healthcare | Generic (ANDA), supplement Labeling | ANDA210016 ↗ |
| Dec 15, 2025 | CLARISCAN GADOTERATE MEGLUMINE | GEHC GE Healthcare | Generic (ANDA), supplement Labeling | ANDA210016 ↗ |
| Nov 21, 2025 | Senographe Pristina 3D Digital breast tomosynthesis | GEHC GE Healthcare | Device approval (PMA), supplement Normal 180 Day Track | P130020 ↗ |
| Jun 23, 2025 | VIZAMYL FLUTEMETAMOL F-18 | GEHC GE Healthcare | New drug (NDA), supplement Efficacy | NDA203137 ↗ |
| Jun 10, 2025 | VIZAMYL FLUTEMETAMOL F-18 | GEHC GE Healthcare | New drug (NDA), supplement Labeling | NDA203137 ↗ |
| May 9, 2025 | OPTISON PERFLUTREN PROTEIN-TYPE A MICROSPHERES ALBUMIN HUMAN | GEHC GE Healthcare | New drug (NDA), supplement Efficacy | NDA020899 ↗ Letter or label ↗ |
| Apr 1, 2025 | MR Contour DL | GEHC GE Healthcare | Device clearance (510(k)) Traditional | K242925 ↗ |
| Mar 5, 2025 | OMNISCAN GADODIAMIDE | GEHC GE Healthcare | New drug (NDA), supplement Labeling | NDA022066 ↗ |
| Mar 5, 2025 | OMNISCAN GADODIAMIDE | GEHC GE Healthcare | New drug (NDA), supplement Labeling | NDA020123 ↗ |
| Feb 4, 2025 | Invenia ABUS Premium, Invenia ABUS Prime Automated breast ultrasound | GEHC GE Healthcare | Device approval (PMA), supplement Normal 180 Day Track | P110006 ↗ |
| Oct 8, 2024 | OMNIPAQUE IOHEXOL | GEHC GE Healthcare | New drug (NDA), supplement Labeling | NDA020608 ↗ Letter or label ↗ |
| Oct 8, 2024 | OMNIPAQUE IOHEXOL | GEHC GE Healthcare | New drug (NDA), supplement Labeling | NDA018956 ↗ Letter or label ↗ |
| Aug 14, 2024 | OMNISCAN GADODIAMIDE | GEHC GE Healthcare | New drug (NDA), supplement Labeling | NDA022066 ↗ Letter or label ↗ |
| Aug 14, 2024 | OMNISCAN GADODIAMIDE | GEHC GE Healthcare | New drug (NDA), supplement Labeling | NDA020123 ↗ Letter or label ↗ |
| Aug 5, 2024 | REGADENOSON REGADENOSON | GEHC GE Healthcare | Generic (ANDA) UNKNOWN | ANDA215955 ↗ |
| Jul 23, 2024 | OMNISCAN GADODIAMIDE | GEHC GE Healthcare | New drug (NDA), supplement Labeling | NDA022066 ↗ |
| Jul 23, 2024 | OMNISCAN GADODIAMIDE | GEHC GE Healthcare | New drug (NDA), supplement Labeling | NDA020123 ↗ |
| Jul 2, 2024 | ViewPoint 6 | GEHC Ge Healthcare GmbH | Device clearance (510(k)) Traditional | K241300 ↗ |
| May 6, 2024 | CERIANNA FLUOROESTRADIOL F-18 | GEHC GE Healthcare | New drug (NDA), supplement Labeling | NDA212155 ↗ |
| Apr 11, 2024 | True Enhance DL | GEHC Ge Healthcare Japan Corporation | Device clearance (510(k)) Traditional | K233698 ↗ |
| Jan 26, 2024 | OMNISCAN GADODIAMIDE | GEHC GE Healthcare | New drug (NDA), supplement Labeling | NDA022066 ↗ Letter or label ↗ |
| Jan 26, 2024 | OMNISCAN GADODIAMIDE | GEHC GE Healthcare | New drug (NDA), supplement Labeling | NDA020123 ↗ Letter or label ↗ |
| Jan 19, 2024 | SIGNA Champion | GEHC Ge Healthcare (Tianjin) Company Limited | Device clearance (510(k)) Traditional | K233728 ↗ |
| Nov 29, 2023 | CLARISCAN GADOTERATE MEGLUMINE | GEHC GE Healthcare | Generic (ANDA), supplement Labeling | ANDA210016 ↗ |
| Oct 27, 2023 | Digital Expert Access with Remote Scanning | GEHC GE Healthcare | Device clearance (510(k)) Traditional | K232346 ↗ |
| Apr 27, 2023 | Precision DL | GEHC GE Healthcare | Device clearance (510(k)) Traditional | K223212 ↗ |
| Apr 25, 2023 | VISIPAQUE IODIXANOL | GEHC GE Healthcare | New drug (NDA), supplement Labeling | NDA020808 ↗ |
| Apr 25, 2023 | OMNIPAQUE IOHEXOL | GEHC GE Healthcare | New drug (NDA), supplement Labeling | NDA020608 ↗ |
| Apr 25, 2023 | VISIPAQUE IODIXANOL | GEHC GE Healthcare | New drug (NDA), supplement Labeling | NDA020351 ↗ |
| Apr 25, 2023 | OMNIPAQUE IOHEXOL | GEHC GE Healthcare | New drug (NDA), supplement Labeling | NDA018956 ↗ |
| Apr 20, 2023 | Deep Learning Image Reconstruction | GEHC Ge Healthcare Japan Corporation | Device clearance (510(k)) Special | K230807 ↗ |
| Apr 6, 2023 | CARESCAPE Canvas 1000, CARESCAPE Canvas Smart Display, CARE… | GEHC GE Healthcare Finland Oy | Device clearance (510(k)) Traditional | K223531 ↗ |
| Mar 1, 2023 | Xeleris V Processing and Review System | GEHC GE Healthcare | Device clearance (510(k)) Traditional | K221680 ↗ |
| Feb 13, 2023 | SIGNA Victor | GEHC Ge Healthcare (Tianjin) Company Limited | Device clearance (510(k)) Traditional | K223439 ↗ |
| Jan 3, 2023 | 3.0T 16ch AIR AA | GEHC Ge Healthcare Coils (Usa Instruments, Inc.) | Device clearance (510(k)) Abbreviated | K223378 ↗ |
| Dec 12, 2022 | INDIUM IN 111 OXYQUINOLINE INDIUM IN-111 OXYQUINOLINE | GEHC GE Healthcare | New drug (NDA), supplement Labeling | NDA019044 ↗ |
| Sep 2, 2022 | Omni Legend | GEHC GE Healthcare | Device clearance (510(k)) Traditional | K221932 ↗ |
| Jul 29, 2022 | Deep Learning Image Reconstruction | GEHC Ge Healthcare Japan Corporation | Device clearance (510(k)) Special | K220961 ↗ |
| Apr 13, 2022 | CARESCAPE B450, E-musb | GEHC GE Healthcare Finland Oy | Device clearance (510(k)) Traditional | K213363 ↗ |
| Apr 13, 2022 | Carescape B850, E-musb | GEHC GE Healthcare Finland Oy | Device clearance (510(k)) Traditional | K213336 ↗ |
| Apr 13, 2022 | CARESCAPE B650, E-musb | GEHC GE Healthcare Finland Oy | Device clearance (510(k)) Traditional | K213181 ↗ |
| Apr 6, 2022 | CERIANNA FLUOROESTRADIOL F-18 | GEHC GE Healthcare | New drug (NDA), supplement Labeling | NDA212155 ↗ |
| Feb 18, 2022 | VISIPAQUE IODIXANOL | GEHC GE Healthcare | New drug (NDA), supplement Labeling | NDA020808 ↗ Letter or label ↗ |
The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 6:31 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates